Working... Menu

RFT-5-dgA in Patients With Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00314093
Recruitment Status : Completed
First Posted : April 12, 2006
Last Update Posted : August 20, 2013
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Ellen Vitetta, University of Texas Southwestern Medical Center

Brief Summary:


  • CD4+ cells are white blood cells that regulate the immune system by controlling the strength and quality of the immune response.
  • CD25+ cells are a subset of CD4+ cells that suppress or prevent immune responses.
  • RFT-5-dgA is an immunotoxin (substance that kills specific cells in the immune system) that kills CD25+ cells.
  • In mouse studies, RFT-5-dgA showed anti-tumor activity in animals studies.

Objective: To determine whether the immune system of patients with metastatic melanoma (melanoma that has spread beyond the original site) can cause tumors to shrink if the patients are given RFT-5-dgA to remove their CD25+ cells.

Eligibility: Patients 18 years of age and older with metastatic melanoma whose disease has progressed after receiving standard treatment.


  • Patients receive RFT-5-dgA through a vein every other day for a total of 3 doses (one treatment course). Patients have routine blood tests during the week of treatment.
  • Four to 5 weeks after the last dose, patients are evaluated with a physical examination, blood tests and scans and x-rays to evaluate their tumor.
  • Patients whose tumor has shrunk or remained stable may be offered additional treatment with RFT-5-dgA up to a total of four courses.
  • Patients undergo leukapheresis or have several tubes of blood drawn from a vein to determine the effects of RFT-5-dgA on the immune system. This is done before the first dose of RFT-5-dgA, after the first three doses, and possibly during subsequent treatment courses in those patients who receive additional treatment. For leukapheresis, blood is collected through a needle in an arm vein and flows through a catheter into a machine that separates it into its components by spinning. The white cells are extracted and the rest of the blood is returned through another needle in the other arm.

Condition or disease Intervention/treatment Phase
Metastatic Melanoma Drug: RFT5pdgA Phase 2

Detailed Description:


  • RFT5-dgA is an immunotoxin comprised of the IL-2Ra-specific murine IgG1 antibody RFT5 linked to deglycosylated ricin A chain (dgA) via the sterically hindered heterobifunctional disulfide linker SMPT (4-succinimidyl-oxycarbonyl-a-methyl-a-(2-pyridyldithio)-toluene).
  • RFT5-dgA is a recombinant immunotoxin that selectively targets CD25 expressing cells in vivo. Further, treatment of human PBMC with RFT5-dgA in vitro results in the preferential depletion of CD25+ Treg cells.
  • Depletion of Treg cells can enhance tumor protection to tumor-associated antigens expressed as self antigens and the RFT5-dgA immunotoxin had potent antitumor effects in SCID mice xenografted with L540 cells which express CD25.
  • The MTD established in the phase I trial of RFT5-dgA was 15mg/m(2)/course IV.


  • The primary objective is to determine whether objective clinical responses can be obtained in patients with metastatic melanoma following administration of RFT5-dgA.
  • Secondary objectives will determine whether changes occur in levels of CD4+CD25+ regulatory T cells (Treg cells) in peripheral blood from before to after treatment and evaluate the toxicity profile of patients treated on this trial.


  • Patients greater than 18 years of age with measurable metastatic melanoma, an expected survival greater than three months, who have progressed after receiving standard therapy will be included.
  • Standard clinical laboratory values must be normal for study inclusion and patients may not be pregnant, breast-feeding or require anticoagulation.
  • Patients must be willing to undergo leukapheresis.
  • Patients with active infections, other major medical disorders, HAMA levels greater than 1 ug/mL, or who have had prior radiotherapy or who have extensive lung disease will be excluded.


  • Patients will receive 3 mg/m(2) RFT5-dgA intravenously every other day for a total of 3 doses (one course).
  • Four to five weeks after the last dose, patients will undergo tumor evaluation, evaluation of changes in T-regulatory cells (CD4+CD25+cells and Foxp3 expression), and toxicity assessment.
  • One additional course may be administered to patients with stable disease or partial or complete response.
  • Up to 41 evaluable patients may be accrued to determine whether theRFT5-dgA can produce a modest response rate targeted to be 20 percent (p1=0.20)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 41 participants
Intervention Model: Single Group Assignment
Masking: Single
Primary Purpose: Treatment
Official Title: Phase II Evaluation of RFT5-dgA in Patients With Metastatic Melanoma
Study Start Date : April 2006
Actual Primary Completion Date : November 2008
Actual Study Completion Date : November 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Melanoma

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

    1. Patients age greater than 18 with measurable metastatic melanoma that have an expected survival of greater than three months will be considered. Patients with resectable local/regional disease would undergo standard treatment with surgical resection and will not be eligible.
    2. Patients must be able to understand and give informed consent.
    3. Patients must have progressed while receiving standard therapy which may include IL-2; however, prior IL-2 therapy is not a requirement for enrollment.
    4. Serum creatinine of 1.6 mg/dl or less.
    5. Total bilirubin 2.0 mg/dl or less, except for patients with Gilbert's Syndrome who must have a total bilirubin less than 3.0 mg/dl.
    6. WBC 3000/mm(3) or greater.
    7. Platelet count 90,000 mm(3) or greater
    8. Serum albumin greater than 2.5 g/dl,
    9. Serum AST/ALT less then 2.5 times normal,
    10. ECOG performance status of 0 or 1 or 2.
    11. For patients greater than 50 years of age or who have a history of cardiovascular disease a thallium stress test is required with EF greater than or equal to 45%.
    12. Patients of both genders must be willing to practice effective birth control during this trial.
    13. Patients must be willing to undergo leukapheresis.


Patients will be excluded:

  1. who are undergoing or have undergone in the past 3 weeks any other systemic form of therapy for their cancer.
  2. who received RFT5-dgA on another trial.
  3. who have uncontrolled concurrent illness including, but not limited to: ongoing or active infection; ongoing or active cardiac disease, such as symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia; or psychiatric illness/social situations that would limit compliance with study requirements.
  4. who require systemic steroid therapy upon entry into the trial.
  5. who are pregnant or breast-feeding.
  6. who are known to be positive for hepatitis B(s)AG, hepatitis C or HIV antibody (because of possible immune effects of these conditions).
  7. who require chronic anticoagulation.
  8. who are 50 years old or greater who do not have a normal stress cardiac test (stress thallium, stress MUGA, dobutamine echocardiogram, or other stress test) with a LVEF less than 45%.
  9. who have history of EKG abnormalities, symptoms of cardiac ischemia or arrhythmias who do not have a normal stress cardiac test (stress thallium, stress MUGA, dobutamine echocardiogram, or other stress test) with a LVEF lea than 45%.
  10. who have any autoimmune diseases or immunodeficiency (including HIV),or other concurrent malignancies.
  11. Who have HAMA levels greater than 1 ug/mL.
  12. Who have had prior radiotherapy including radiotherapy to the lung, except for patients who have undergone localized soft tissue radiotherapy.
  13. Who have extensive lung disease where greater than 15% of the lung is involved based on CT evaluation.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00314093

Layout table for location information
United States, Maryland
National Cancer Institute (NCI)
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
University of Texas Southwestern Medical Center
National Cancer Institute (NCI)

Additional Information:
Layout table for additonal information
Responsible Party: Ellen Vitetta, Director, University of Texas Southwestern Medical Center Identifier: NCT00314093     History of Changes
Obsolete Identifiers: NCT00331461
Other Study ID Numbers: 060137
First Posted: April 12, 2006    Key Record Dates
Last Update Posted: August 20, 2013
Last Verified: August 2013

Keywords provided by Ellen Vitetta, University of Texas Southwestern Medical Center:
Clinical Response
Stage IV Melanoma
T Regulatory Cells
CD25+ Cells
Metastatic Melanoma

Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas